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The role of palliative chemotherapy in metastatic non small cell 
lung cancer with brain metastases
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Background: The overall risk of developing brain metastases in 
non-small cell lung cancer (NSCLC) is 20%. Palliative chemotherapy 
improves the outcome of metastatic NSCLC but there is no evidence 
to support its use in the presence of brain metastases. A retrospective 
analysis of NSCLC patients with brain metastases was performed to 
determine the value of chemotherapy within this group of patients.
Methods: Patients with NSCLC who received palliative whole brain 
radiotherapy (WBRT) for brain metastasis between January 2002 and 
April 2005 were identiﬁed from the radiotherapy database. Case notes 
and electronic records were analysed retrospectively. The primary 
endpoint was overall survival (OS) calculated from the date of con-
ﬁrmation of brain metastases and estimated using the Kaplan-Meier 
method. A multivariate analysis was performed using Cox regression to 
examine the effect of prognostic variables.
Results: A total of 162 patients were identiﬁed. 87 patients (53.7%) 
had brain metastases at presentation. In addition to WBRT, 4 patients 
(2.5%) underwent surgical resection of brain metastases. 1 patient had 
stereotactic radiosurgery. 59 patients (36.4%) received chemotherapy 
following WBRT. The median number of cycles of chemotherapy 
administered following WBRT was 3 (range 1-6). Median OS was 3.84 
months (95% CI 3.22 to 4.83 months) and 1 year survival 9.3%. Pa-
tients who were performance status (PS) 0-1 had a median OS of 6.47 
months versus 2.63 months for those who were PS 2-3 (HR=2.08; 95% 
CI 1.48 to 2.92; p<0.0001). Patients receiving chemotherapy following 
WBRT had a median OS of 6.47 months versus 2.60 months for those 
who did not receive chemotherapy (HR=0.45; 95% CI 0.32 to 0.63; 
p<0.0001). In multivariate analysis, chemotherapy following WBRT 
remained a signiﬁcant favourable prognostic factor after controlling for 
performance status, age, histological subtype, number and sites of brain 
metastases, synchronicity of brain metastases, dose of radiotherapy and 
presence of other distant metastases.
Conclusion: Palliative chemotherapy following WBRT in patients with 
metastatic NSCLC with brain metastases improves survival and should 
be considered in good performance status patients.
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A phase II study of vinorelbine monotherapy in the treatment of 
advanced non-small cell lung cancer in elderly Chinese population
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tal, Hong Kong, China
Introduction: Non-small cell lung cancer (NSCLC) has accounted 
for more than 3,000 new cases each year in Hong Kong with 5-year 
survival less than 15%. Chemotherapy is currently the “gold standard” 
treatment for advanced disease in those relatively young ( <70 years 
old) with good performance status. However the beneﬁt of chemo-
therapy in the elderly has been limited by the concerns about toxicities, 
which may have ethnic differences. 
Method: A phase II single-centered open-labelled study, using vinorel-
bine (30mg/m2 ivi on day 1 and 8, every 3 weeks, for 6 cycles) in 
chemonaive elderly Chinese patients (>70 years old) with cytologically 
or histologically conﬁrmed stage IIIB/IV NSCLC. 
Results: There were 18 patients recruited (age 74 ± 3 years, 10 males, 
33% never smokers) with good performance status (all in WHO 0 
or 1). The majority of cases were adenocarcinomas (56%) and more 
than two-thirds in stage IIIB. Dose reduction was required because of 
myelosuppression in 9.9%. The median number of cycles administered 
was 4, with 6 patients managed to complete 6 cycles of chemotherapy. 
The objective tumour response rate was 11.1% with 33.3% stable 
disease. The median survival was 10 months. Signiﬁcant grade 3/4 
toxicities occurred in neutropenia (68%), anaemia (1%), and phlebitis 
(4%). There was no treatment-related death.
Conclusion: Vinorelbine as a single agent is active in the treatment 
of advanced NSCLC in the elderly Chinese with acceptable toxicity 
proﬁle. Future study comparing with combination chemotherapy is 
warranted.
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Background: In recent randomized phase III trials in early-stage 
NSCLC, cisplatin-based adjuvant chemotherapy resulted in a 4.1-15% 
5-year survival beneﬁt versus observation. However, only 56-74% of 
patients completed planned treatment, suggestive of poor compliance. 
C plus G (CG), one of the standard regimens for advanced NSCLC, is 
considered more tolerable than other platinum-based regimens because 
it is associated with less nausea/vomiting, sensory neuropathy, and 
alopecia. The objective of this study was to assess the feasibility and 
safety of adjuvant CG in patients with completely resected NSCLC. 
Methods: Eligibility criteria included histologically conﬁrmed 
NSCLC, age 20-74 years, complete surgical resection, post-operative 
pathological stage IB-III, 4-8 weeks post-surgery, ECOG performance 
status (PS) 0-1, adequate organ function, and informed consent. Pa-
tients were treated with adjuvant CG (C, AUC=5 on day 1; G, 1,000 
mg/m2 on days 1 and 8) every 3 weeks for 4 cycles. The primary 
endpoint was treatment compliance, and the planned sample size was 
35 patients (Simon’s minimax design). 
Results: From October 2004 to July 2006, 35 patients (17 males, 18 
females; median age, 64 years) were enrolled. All patients had PS=0. 
Histologic types included adenocarcinoma (n=27), squamous cell 
carcinoma (n=3), large cell neuroendocrine carcinoma (n=3), large cell 
carcinoma (n=1), and adenosquamous carcinoma (n=1). Pathological 
stages included stage IB (n=7), stage IIA (n=7), stage IIB (n=4), stage 
IIIA (n=13), and stage IIIB (n=4). Resection consisted of lobectomy 
(n=33) and pneumonectomy (n=2). All patients received ≥2 cycles 
of chemotherapy, with 29 patients (83%) completing 3 or 4 cycles. 
Primary G3/4 toxicities were leukopenia (51%), neutropenia (83%), 
thrombocytopenia (71%), and anemia (38%). Nonhematologic toxici-
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ties were very mild: 6% G3/4 febrile neutropenia, 3% infection, and 
3% rash. No treatment-related deaths occurred. 
Conclusion: Adjuvant CG in patients with completely resected 
NSCLC is well tolerated, and treatment compliance is very good.
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CYFRA 21-1 as an early predictor to response to first line 
chemotherapy in advanced non small cell lung cancer.
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Background: In an era of ever evolving, promising new therapies for 
advanced non small cell lung cancer, early predictors of response to 
therapy, are needed. We evaluated early variations in CYFRA 21-1 
serum levels of patients with advanced NSCLC receiving ﬁrst line che-
motherapy and correlated the results with objective tumor response. 
Patients and Methods: 29 consecutive, previously untreated, patients 
of advanced non small cell lung cancer,excluding those with brain me-
tastases, with measurable disease on CT scan were evaluated. All pa-
tients were treated with conventional systemic chemotherapy, although 
the choice of chemotherapy was left to the discretion of the treating 
physicians. Serum samples were obtained immediately before the start 
of 1st and 2nd cycles of chemotherapy. CYFRA 21-1 was measured with 
an electrochemiluminescense immunoassay on an automatic analyzer 
(Elecsys 2000; Roche Diagnostics). Response was evaluated using 
Response evaluation criteria in solid tumors (RECIST) criteria.
Results: 10 patients had partial response, 9 patients had stable disease 
and 9 had progressive disease. None of the patients had complete 
response. 21/29 i.e. 72 % patients had an elevated baseline value of 
CYFRA 21-1. 62 % patients (18/29) had a decrease in CYFRA 21-1 
after 1 cycle of chemotherapy. The average reduction in the 2nd reading 
was irrespective of whether baseline value was normal or not. The 
average reduction was statistically signiﬁcant (P = 0.002; 95% CI, from 
0.8369 to 3.49464; paired sample t test). 8 out of 10 (80%) patients 
with partial response had a reduction in their 2nd reading of. CYFRA 
(P= 0.019; 95% CI, from 0.81965 to 7.20035; paired sample t test) 
which was signiﬁcant. We also observed that 6/9 (66%) patients whose 
disease remains stable also had a decrease in their subsequent reading 
(P=0.0106; 95% CI, from - 0.44942 to 3.82720; paired sample t test), 
though it was not signiﬁcant statistically. Although 5 out of 9 (55%) 
patients, who had an increase in their 2nd reading had progressive 
disease, but it was not statistically signiﬁcant (P= 0.537; 95% CI, from 
-1.20021 to 2.13354; paired sample t test). 14 out of 19 (73%) who ei-
ther had partial response or had stable disease, had a reduction in their 
2nd value of CYFRA and was signiﬁcant statistically (P 0.004; 95% CI, 
from 0.74792 to 3.50208; paired sample t test). We also observed that 
except for 1 patient, all patients who had a decrease of 42% or more, 
were those who had either responded to chemotherapy or had stable 
disease (P 0.001), which was statistically signiﬁcant.
Conclusion: We conclude that monitoring of serum marker CYFRA 
21-1, early during ﬁrst-line chemotherapy may be a useful prognostic 
tool for evaluation of early tumor response in patients with advanced 
NSCLC
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Subjective Reasons for Patient Preference for Oral or Intravenous 
Vinorelbine in the Treatment of Advanced Non-small Cell Lung 
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Background: Stage IIIB and IV non-small cell lung cancer (NSCLC) 
is incurable and treatment with chemotherapy aims at reducing 
symptoms and prolonging survival. Life time expectancy is short and 
any treatment should allow a maximum of patient autonomy to fulﬁll 
personal wishes and preferences. It has a major inﬂuence on every 
day life to receive chemotherapy; either positive with attention and 
care or negative with distressing time spend at the clinic. Vinorelbine 
is available in an oral (PO) or intravenous (IV) formulation. The PO 
treatment can be administered at home without the need for an IV line 
at the clinic. The opportunity could be resource sparing for the health 
care system and for patient transportation, but little is known about the 
patients’ preference. The aim of the present study was to explore the 
subjective reasons for patients choosing PO or IV treatment in a clinical 
setup.
Methods: The study included 61 patients with stage IIIB or IV NSCLC 
in a previously reported randomized cross-over trial. The patients were 
randomly allocated to two cycles of IV vinorelbine followed by two 
cycles of PO vinorelbine or the opposite sequence. Each cycle was 
combined with IV carboplatin day one and vinorelbine was given day 
one and eight. Antiemetics were added both day one and eight. After re-
ceiving four cycles, the patients had a free choice of IV or PO vinorel-
bine for the last two cycles. This choice was regarded as the patient’s 
preference. A questionnaire was ﬁlled in after four cycles to explore 
and quantify the subjective reasons for selecting a treatment. Sixteen 
questions were asked on a ﬁve-point scale. The median answers were 
used to estimate the group opinion and comparisons between groups 
were done by Wilcoxon test.
Results: Forty-three patients completed four cycles and made a 
choice for IV vinorelbine (n=11, 26%) or PO vinorelbine (n=32, 74%) 
(p<0.001) independently of treatment arm (p=0.94) and sex (p=0.94). 
The median age for patients choosing IV or PO was 59 and 63 years, 
respectively (p=0.24). Side effects reported after each cycle did not 
correlate with the patients’ preference. Forty patients ﬁlled in the ques-
tionnaire. In general, it was the subjective conception that pills and IV 
treatment had equal efﬁciency in treating the cancer. Patients with pref-
erence for IV treatment agreed that pills had more side effects than IV, 
whereas patients preferring PO did not ﬁnd any differences. The daily 
life was less affected by pills than infusions in patients with preference 
for PO but not for the IV group. Patients who chose IV vinorelbine 
were more concerned about the risk of forgetting the pills, vomiting up 
the pills, and taking them at home.
Conclusions: In a randomized cross-over study where patients experi-
enced both IV and PO vinorelbine in combination with IV carboplatin, 
the major part (74%) preferred PO treatment.
Although not reﬂected in toxicity grading during the study, the major 
subjective reason for choosing IV vinorelbine was more side effects 
with pills and patients choosing PO vinorelbine found that the pills 
affected daily life less.
